Pancreatic Cancer Research

ResearcherKyushu UniversityNo recent work listed

Motofumi Kumazoe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3002-2994; OpenAlex author ID A5009883829. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2017: 3 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 4

  1. PPAR/PDK4 pathway is involved in the anticancer effects of cGMP in pancreatic cancer. First author DOI 10.1016/j.bbrc.2023.06.043↗
  2. FOXO3 is essential for CD44 expression in pancreatic cancer cells. Co-author DOI 10.1038/onc.2016.426↗
  3. PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-017-02162-9↗
  4. The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. Co-author DOI 10.1074/jbc.m116.772111↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirofumi Tachibana · 4 shared papers, 2017–2023 · strength 0.38
  2. Mai Yamashita · 2 shared papers, 2017–2023 · strength 0.26
  3. Yoshinori Fujimura · 1 shared paper, 2023 · strength 0.20
  4. Masaharu Murata · 1 shared paper, 2017 · strength 0.06
  5. Shuntaro Tsukamoto · 1 shared paper, 2017 · strength 0.06
  6. Takashi Takahashi · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.